ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

Authors

Stephen T. Oh, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

2020

Volume

4

Issue

18

First Page

4282

Last Page

4291

Document Type

Open Access Publication

DOI

10.1182/BLOODADVANCES.2020002662

Rights and Permissions

Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Ruben Mesa, Carole B. Miller, Candido E. Rivera, Angela G. Fleischman, Swati Goel, Mark L. Heaney, Casey O’Connell, Murat O. Arcasoy, Yafeng Zhang, Jun Kawashima, Tomas Ganz, Mark Kowalski, Carrie Baker Brachmann; ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv 2020; 4 (18): 4282–4291. doi: https://doi.org/10.1182/bloodadvances.2020002662

Recommended Citation

Oh, Stephen T. and al., et, "ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial." Blood Advances. 4, 18. 4282 - 4291. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9664